TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants of Treatment Related Adverse Events (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Variation of the functional score of WOMAC
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in serum VEGF values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum VCAM-1 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum NRP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC Metabolite Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of words correctly named
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Expression level of ephrin-B1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: visual capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: center point thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Caloric value of breastmilk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Change of Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Insulin-like Growth Factor-1 (IGF-1) Plasma Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of Quality of Life Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hypoglycemia symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in superficial femoral plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Treatment Related Mortality (TRM)
Endpoint domain: Mortality/survival
Primary endpoint: change in plasma soluble CD14 (sCD14)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average age-adjusted MAC of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum CTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: All stroke, death, and MI
Endpoint domain: Mortality/survival
Primary endpoint: Ipsilateral stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Favorable 3-month outcome rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: anesthesia time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in arterial stiffness (carotid-femoral pulse wave velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relapse of psychosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in prevalence of growth faltering during the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in prevalence of growth faltering post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antimicrobial resistance of H. pylori isolate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cognitive function - sustained attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive function - psychomotor speed
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive function - working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive function - mental flexibility
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive function - mental state
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Risk of opioid misuse
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of ≥50% stenosis in the coronary artery tree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Interruptions of procedures for respiratory events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Participants Experiencing Ventricular Fibrillation Requiring Defibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Permanent Product Measure of Performance (PERMP) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure of conservative management of placenta accreta spectrum
Endpoint domain: Adverse events/effects
Primary endpoint: Variability of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of enrollment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability of simulation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Procedure related adverse outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Non-serious Adverse Event (nSAE) and Any Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal Amount of Air Forcefully Exhaled in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time until nausea is achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of cardiovascular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Activation of signaling pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of telemedical risk assessment and preoperative evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient acceptance of telemedical preanesthesia evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction with telemedical preanesthesia evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urinary cortisol and catecholamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: quantitative analysis of CK-19 mRNA CTCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First time to receive morphine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Cerebral Perfusion Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of catheter-associated urinary tract infection (CAUTI)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from baseline in insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Oral hygiene assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal status- periodontal pockets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal status-tooth mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal status- bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficiency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development and/or severity of mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure of high perianal fistulas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduce incontinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in hepatic fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Functional Independence Measure v4 at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Functional Independence Measure v4 at 3 months post-discharge
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Functional Independence Measure v4 at 6 months post-discharge
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: State-Trait Anxiety Inventory for Adults
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Beck's Depression Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The PTSD Checklist for DSM-5 (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of pFAK Inhibition in Tumor Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline on adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Serious, Acute, Bacterial Infections (SABIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Spontaneous pain on numerical rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evoked pain on numerical rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of riociguat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of riociguat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of riociguat main metabolite M1 (BAY 60-4552)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of riociguat main metabolite M1 (BAY 60-4552)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in MADRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of self-monitoring of blood glucose tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Toilet training completion age
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Aerobic Fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Fatness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C-reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Breast Cancer Death Rate
Endpoint domain: Mortality/survival
Primary endpoint: Breast Cancer Incidence
Endpoint domain: Mortality/survival
Primary endpoint: Number of subjects with abnormal findings in physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with abnormal changes in laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinically significant changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with clinically significant changes in 12-lead ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of viable tumor cells at the margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Development of persistent AF
Endpoint domain: Mortality/survival
Primary endpoint: Muscle Onset Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in episodes of faecal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Length of Stay in Hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Best Overall Response (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Heart Rate Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With Dose-limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Who Survive for at Least 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Biochemically-validated abstinence at 6-month
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Biochemically-validated abstinence at 12-month
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to return of normal bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Magnitude of Medial Olivocochlear Reflex Inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goodman and Kruskal gamma coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 75g oral glucose tolerance test (OGTT) positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High Mobility Group Box-1 (HMGB1) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement/Change in Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bleeding on Probing (BoP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Male Partners Counseled and Tested for HIV During Pregnancy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to glycaemic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: remission rate of type 2 diabetes at a year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in Bone Mineral Density (BMD) According to rs700518 Polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in Bone Mineral Density (BMD) According to rs1062033 Polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in the Physical Component Scale (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Subjects With at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Type of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Adverse Events as Determined by the Investigator
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Event Relatedness to Study Drug as Reported by the Investigator
Endpoint domain: Adverse events/effects
Primary endpoint: Dose Adjustment Upon Incidence of an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Outcome of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Headache Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response probability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of Reported Concussions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rapid virologic response (RVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: short term outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular events (death, myocardial infarction, stroke, recurrent ischemia, urgent coronary revascularization)
Endpoint domain: Mortality/survival
Primary endpoint: late toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: number of lymph nodes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Effect size of Control-to-Range (CTR) vs. Continuous Glucose Monitor (CGM)-augmented insulin pump treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity and interference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Purchase of Spectacles
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sustained implantation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Serum FSH levels below the lower limit of quantitation (LLOQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: stable, sustained mixed donor-host chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Remained Alive Without Evidence of Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Peak Plasma 2-AAA Concentration Percentage Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluctuation in Pupil Diameter (Hippus)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Heart Rate Variability in the High Frequency Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants completing the DOC Screen in 5 minutes or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean astigmatic correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean surgically induced astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dose limiting toxicity (DLT) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamics of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: therapeutic effects on dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative Nausea and Vomiting Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-albuterol Forced Expiratory Volume in One Second (FEV1) <80% Predicted Normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Genetic and transcriptomic landscape
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected QT interval (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With AEs Leading to Withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Death
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Genetron Lung Cancer Panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients With Arrhythmia Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in self-reported nutrition practices
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Delusion Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elbow extension range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thoracic kyphosis orientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thoracic spine extension range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delta Eed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: delta RV volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients who do not receive any more catecholamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Memorial Symptom Assessment Scale-Short Form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Retinal and choriocapillaris features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical change of alopecia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of FFRangio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes